Upload Avatar (500 x 500)
Weiqiang Lu
Life Science
East China Normal University
Shanghai
Language: Chinese, English
Gpcr
Tumor
Immune Regulation
Signaling
Cell Signaling
Molecular Mechanisms
Drug Development
Cancer Therapy
Receptor
Pharmacology
Clinical Trials
Molecular Targets
Receptor Antagonists
Medicinal Chemistry
Tumor Environment
Innovation
Areas of Focus
- GPCR and tumor immune regulation
- Development of anti-tumor drugs targeting GPCR
Work Experience
- 2013-2017: Assistant Researcher, Morning Scholar at East China Normal University, School of Life Sciences
- 2018-2022: Associate Researcher at East China Normal University, School of Life Sciences
- 2022-present: Researcher at East China Normal University, School of Life Sciences
Academic Background & Achievements
- 2004-2008: Bachelor's Degree from East China University of Science and Technology
- 2008-2013: PhD from East China University of Science and Technology
Publications
- PPIA dictates NRF2 stability to promote lung cancer progression, Weiqiang Lu*, Jiayan Cui, Wanyan Wang, Qian Hu, Yun Xue, Xi Liu, Ting Gong, Yiping Lu, Hui Ma, Bo Feng, Qi Wang, Naixia, Zhang, Mingyao Liu, Ruth Nussinov, Feixiong Cheng, Hongbin Ji, Jin Huang*
- Subtle Structural Changes across the Boundary between A2AR/A2BR Dual Antagonism and A2BR Antagonism: A Novel Class of 2-Aminopyrimidine-based Derivatives, Haojie Wang, Xinyu Yang, Yan Li, Shuyin Ze, Bo Feng, Mingyao Liu, Qiong Xie*, Yonghui Wang*, Weiqiang Lu*, 2024
- Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[d]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD), Ruoqing Zeng, Meimiao Fang, Ancheng Shen, Xiaolei Chai, Yumiao Zhao, Mingyao Liu, Lingfeng Zhu, Weiwei Rui, Bo Feng, Liang Hong, Chunyong Ding, Zilan Song*, Weiqiang Lu*, Ao Zhang*, 2024
- Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia, Hui Ma, Jiayan Cui, Zehui Liu, Wenqing Fang, Sisi Lu, Shuying Cao, Ji-an Chen, Lixue Lu, Qiong Xie, Yonghui Wang, Ying Huang, Kongfei Li, Hongyan Tong, Jin Huang*, Weiqiang Lu*, 2023
- Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy, Chenyu Zhu, Shuyin Ze, Ronghui Zhou, Xinyu Yang, Haojie Wang, Xiaolei Chai, Meimiao Fang, Mingyao Liu, Yonghui Wang*, Weiqiang Lu*, Qiong Xie*, 2023
- Discovery of 2H-Indazole-3-carboxamide Derivatives as Novel Potent Prostanoid EP4 Receptor Antagonists for Colorectal Cancer Immunotherapy, Zhiyuan Cheng, Yijie Wang, Yao Zhang, Chan Zhang, Mengru Wang, Wei Wang, Hankun Zhang, Qiansen Zhang, Chunyong Ding, Deyan Wu, Linlin Yang, Mingyao Liu*, Weiqiang Lu*, 2023
- Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia, Chunyang Yi, Jiacheng He, Dan Huang, Yumiao Zhao, Chan Zhang, Xiyun Ye, Ying Huang, Ruth Nussinov, Junke Zheng*, Mingyao Liu*, Weiqiang Lu*, 2022
- Scaffold Hopping Strategy to Identify Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy, Wei Wang, Jiacheng He, Junjie Yang, Chan Zhang, Zhiyuan Cheng, Yao Zhang, Qiansen Zhang, Peili Wang, Shuowen Tang, Xin Wang, Mingyao Liu*, Weiqiang Lu*, Zhang Hankun*, 2022
- Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8 H)-one Derivatives as Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy, Fazhi Yu, Chenyu Zhu, Shuyin Ze, Haojie Wang, Xinyu Yang, Mingyao Liu, Qiong Xie*, Weiqiang Lu*, Yonghui Wang*, 2022
- From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis, Beier Jiang, Xingwu Jiang, Qiansen Zhang, Qiuwen Liang, Ziliang Qiu, Xiangbai Sun, Junjie Yang, Si Chen, Chunyang Yi, Xiaolei Chai, Mingyao Liu, Lifang Yu*, Weiqiang Lu*, HanKun Zhang*, 2021
- Reprogramming Immunosuppressive Myeloid Cells Facilitates Immunotherapy for Colorectal Cancer, Weiqiang Lu*, Weiwei Yu, Jiacheng He, Wenjuan Liu, Junjie Yang, Xianhua Lin, Yuanjin Zhang, Xin Wang, Wenhao Jiang, Jian Luo, Qiansen Zhang, Huaiyu Yang, Shihong Peng, Zhengfang Yi, Shancheng Ren, Jing Chen, Stefan Siwko, Ruth Nussinov, Feixiong Cheng, Hankun Zhang*, Mingyao Liu*, 2021
- Discovery and Characterization of 1 H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy, JunJie Yang, WeiWei Yu, LongLong Hu, WenJuan Liu, XianHua Lin, Wei Wang, Qiansen Zhang, PeiLi Wang, ShuoWen Tang, Xin Wang, Mingyao Liu, Weiqiang Lu *, HanKun Zhang*, 2020
- A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling, Yujie Huang, Jiansong Fang*, Weiqiang Lu*, Zihao Wang, Qi Wang, Yuan Hou, Xingwu Jiang, Ofer Reizes, Justin Lathia, Ruth Nussinov, Chris Eng, Feixiong Cheng*, 2019
Awards
- 2018: 22nd Chinese Pharmacological Society Young Pharmacologist Award
- 2019: 16th National Biochemistry and Molecular Pharmacology Conference Young Excellent Paper First Prize
- 2020: 'Internet+' College Students Innovation and Entrepreneurship Excellent Instructor
- 2021: 5th National Matrix Biology Conference Young Report Second Prize
- 2023: Shanghai Eastern Talent Program Young Project
